Instructions for Iniectran (Chondroitin sulfate) 10 ampoules
English product name
Iniectran
Release form Iniectran
Solution for injection in/m
Description Iniectran:
The solution for in/m injection is transparent, colorless or slightly yellowish.
1 ml
chondroitin sodium sulfate 100 mg
Auxiliary substances: sodium disulphite - 2 mg, methylparahydroxybenzoate - 0.5 mg, 1M solution of sodium hydroxide - up to pH 6.0-7.5, water d/i - up to 1 ml.
ATC codes
M01AX25 Chondroitin sulfate
Clinical-pharmacological groups / Group affiliation
Preparation for controlling the metabolism in cartilage tissue
Active substance
Chondroitin sulfate
Pharmacotherapy group
Tissue repair stimulator
Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light, at a temperature not higher than 25 ° C.
Best before date
Shelf life is 3 years.
Testimony Iniectran:
- Degenerative-dystrophic diseases of joints and spine:
- osteoarthrosis of peripheral joints;
- intervertebral osteochondrosis and osteoarthrosis.
- To accelerate bone marrow formation in fractures.
Method of use, course and dosage Iniectran:
B/m, one ml every other day. If tolerable, the dose is increased to two ml, starting with the fourth injection. Treatment course - 25-35 injections. If necessary, a second course of treatment may be carried out after 6 months. The duration of the repeated treatment is determined by the doctor.
For bone marrow formation, the course of treatment is three to four weeks (10-14 injections every day).
- Nosology Chondroitin sulfate (ICD codes)
- M15
- Polyarthrosis
- M42
- Osteochondrosis of the spine
- M47
- Spondylosis
- T14.2
- Fracture in an unspecified area of the body
Pharmacological effect:
Chondroitin sulfate is the main component of proteoglycans, which together with collagen fibres of cartilage matrix.
It has a chondrostimulating, regenerating, anti-inflammatory and analgesic effect.
Chondroitin sulfate is involved in the construction of the main substance of cartilage and bone tissue. Has
chondroprotective properties; enhances metabolic processes in hyaline and fibrous cartilage and subchondral bone; suppresses the activity of enzymes that cause the degradation (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes;
It has an effect on the phosphorus-calcium exchange in cartilage tissue, stimulates its regeneration, and is involved in the construction of the main substance of bone and cartilage tissue. It has anti-inflammatory and analgesic properties, contributes to the reduction of the release of inflammation mediators and pain factors into the synovial liquid through synoocytes and macrophages of the synovial shell, and suppresses the secretion of leukotrienes and prostaglandins. The preparation prevents the degeneration of connective tissue and reduces calcium losses, and accelerates bone tissue regeneration processes.
Chondroitin sulfate slows the progression of osteoarthrosis and osteochondrosis. It promotes restoration of joint bags and cartilage surfaces of joints, prevents collapse of connective tissue, normalizes production of joint fluid.
The clinical effect is manifested by the improvement of joint mobility and the reduction of pain intensity, while the therapeutic effect is preserved long after the end of the course of therapy. In the treatment of degenerative joint changes accompanied by secondary synovitis, the effect is observed in two to three weeks from the beginning of the course.
